Substantia Nigra in Parkinson's Disease: a Multimodal MRI Comparison Between Early and Advanced Stages of the Disease
Overview
Authors
Affiliations
This study focused on the substantia nigra (SN) in Parkinson's disease (PD). We measured its area and volume, mean diffusivity (MD), fractional anisotropy (FA) and iron concentration in early and late PD and correlated the values with clinical scores. Twenty-two early PD (EPD), 20 late PD (LPD) and 20 healthy subjects (age 64.7 ± 4.9, 60.5 ± 6.1, and 61 ± 7.2 years, respectively) underwent 1.5 T MR imaging with double-TI-IR T1-weighted, T2*-weighted and diffusion tensor imaging scans. Relative SN area, MD, FA and R2* were measured in ROIs traced on SN. Correlation with Unified Parkinson Disease Rating Scale (UPDRS) scores was assessed. In LPD, the SN area was significantly reduced with respect to EPD (p = 0.04) and control subjects (p < 0.001). In EPD, the SN area was also significantly smaller than in controls (p = 0.006). Similarly, the SN volume significantly differed between LPD and controls (p = 0.001) and between EPD and LPD (p = 0.049), while no significant differences were found between controls and EPD. Both SN area (r = 0.47, p = 0.004) and volume (r = 0.46, p = 0.005) correlated with UPDRS scores. At 1.5 T, SN morphological measurements were sensitive to early PD changes and able to track the disease progression, while MD and FA measures and relaxometry did not provide significant results.
Meng H, Zhang D, Sun Q Head Face Med. 2023; 19(1):25.
PMID: 37386479 PMC: 10308637. DOI: 10.1186/s13005-023-00371-4.
Nigral diffusivity, but not free water, correlates with iron content in Parkinson's disease.
Langley J, Huddleston D, Hu X Brain Commun. 2021; 3(4):fcab251.
PMID: 34805996 PMC: 8599079. DOI: 10.1093/braincomms/fcab251.
Depierreux F, Parmentier E, Mackels L, Baquero K, Degueldre C, Balteau E NPJ Parkinsons Dis. 2021; 7(1):57.
PMID: 34238927 PMC: 8266835. DOI: 10.1038/s41531-021-00199-2.
Extra-basal ganglia iron content and non-motor symptoms in drug-naïve, early Parkinson's disease.
Kim M, Yoo S, Kim D, Cho J, Kim J, Ahn J Neurol Sci. 2021; 42(12):5297-5304.
PMID: 33860863 PMC: 8642382. DOI: 10.1007/s10072-021-05223-0.
He N, Langley J, Huddleston D, Chen S, Huang P, Ling H Neuroimage Clin. 2020; 28:102391.
PMID: 32889398 PMC: 7479276. DOI: 10.1016/j.nicl.2020.102391.